BDNF and myeloid sarcoma: On the other hand, older age and greater disability in Met carriers are expected to increase the proportion of CI in this group: in this respect, as commented above, our findings seem to reinforce the hypothesis of a protective effect of BDNF polymorphism against CI in MS.